| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David C. Hastings | Chief Financial Officer | 2025-02-04 | 22,183 | $3.28 | $72.83kSell |
| Michael J. McElhaugh | Interim President CEO | 2025-02-04 | 23,790 | $3.28 | $78.10kSell |
| J. Christopher Naftzger | General Counsel and CCO | 2025-02-04 | 11,333 | $3.28 | $37.21kSell |
| Karen Sims | Chief Medical Officer | 2025-02-04 | 19,348 | $3.28 | $63.52kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Roivant Sciences Ltd | 20.26% | 38,847,462 | $172.48M | Insider |
| Matthew Gline | 20.26% | 38,847,462 | $172.48M | Insider |
| Dexxon Holdings Ltd | 16.71% | 32,027,080 | $142.20M | Insider |
| Morgan Stanley | 12.60% | 24,162,383 | $107.28M | Institution |
| Vivek Ramaswamy | 8.38% | 16,068,455 | $71.34M | Insider |
| Viking Global Performance LLC | 8.35% | 16,013,540 | $71.10M | Insider |
| Viking Global Investors LP | 8.35% | 16,013,540 | $71.10M | Insider |
| Rose Sharon Shabet | 8.35% | 16,013,540 | $71.10M | Insider |
| Svf Investments Uk Ltd | 8.35% | 16,013,540 | $71.10M | Insider |
| Patrick MacHado | 8.35% | 16,013,540 | $71.10M | Insider |